<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23510391</article-id>
      <article-id pub-id-type="pmc">3600022</article-id>
      <article-id pub-id-type="publisher-id">1471-2407-13-100</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2407-13-100</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A1">
          <name>
            <surname>Modena</surname>
            <given-names>Piergiorgio</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>pmodena@cro.it</email>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" id="A2">
          <name>
            <surname>Sardi</surname>
            <given-names>Iacopo</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>i.sardi@meyer.it</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Brenca</surname>
            <given-names>Monica</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mbrenca@cro.it</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Giunti</surname>
            <given-names>Laura</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>l.giunti@meyer.it</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Buccoliero</surname>
            <given-names>Anna Maria</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>am.buccoliero@meyer.it</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Pollo</surname>
            <given-names>Bianca</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>Bianca.Pollo@istituto-besta.it</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Biassoni</surname>
            <given-names>Veronica</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>veronica.biassoni@istitutotumori.mi.it</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Genitori</surname>
            <given-names>Lorenzo</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>l.genitori@meyer.it</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Antonelli</surname>
            <given-names>Manila</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>manila_antonelli@yahoo.it</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Maestro</surname>
            <given-names>Roberta</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>maestro@cro.it</email>
        </contrib>
        <contrib contrib-type="author" id="A11">
          <name>
            <surname>Giangaspero</surname>
            <given-names>Felice</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <xref ref-type="aff" rid="I7">7</xref>
          <email>felice.giangaspero@uniroma1.it</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A12">
          <name>
            <surname>Massimino</surname>
            <given-names>Maura</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>maura.massimino@istitutotumori.mi.it</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Unit of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, 33081, Italy</aff>
      <aff id="I2"><label>2</label>Department of Onco-hematology, Meyer Pediatric Hospital, Firenze, Italy</aff>
      <aff id="I3"><label>3</label>Department of Pathology, C. Besta Neurologic Institute, Milano, Italy</aff>
      <aff id="I4"><label>4</label>Department of Pediatric Oncology I.R.C.C.S, &#x201C;Istituto Nazionale Tumori&#x201D;, Milano, 20131, Italy</aff>
      <aff id="I5"><label>5</label>Department of Neuro-Surgery, Meyer Pediatric Hospital, Firenze, Italy</aff>
      <aff id="I6"><label>6</label>Department of Pathology, Sapienza University, Policlinico Umberto I, Roma, 00161, Italy</aff>
      <aff id="I7"><label>7</label>I.R.C.C.S. &#x201C;Neuromed&#x201D;, Pozzilli, Italy</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>13</volume>
      <fpage>100</fpage>
      <lpage>100</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>10</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>2</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2013 Modena et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Modena et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2407/13/100"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Atypical teratoid rhabdoid tumor (ATRT) patients display a dismal median overall survival of less than 1&#xA0;year. A consistent fraction of cases carries de-novo <italic>SMARCB1/INI1</italic> constitutional mutations in the setting of the &#x201C;rhabdoid tumor predisposition syndrome&#x201D; and the outcome is worst in infant syndromic ATRT patients.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We here describe a patient affected by mosaic Klinefelter syndrome and by rhabdoid tumor predisposition syndrome caused by constitutional <italic>SMARCB1/INI1</italic> heterozygous mutation c.118C&gt;T (Arg40X). Patient&#x2019;s ATRT primary tumor occurred at 2&#xA0;years of age concurrent with metastatic lesions. The patient was rendered without evidence of disease by combined surgery, high-dose poli-chemotherapy and craniospinal irradiation, followed by autologous hematopoietic stem cell transplantation. At the onset of a spinal lesion 5.5&#xA0;years later, both tumors were pathologically and molecularly evaluated at the national central pathology review board and defined as ATRT in a syndromic patient, with strong evidence of a clonal origin of the two lesions. The patient was then treated according to SIOP guidelines and is now alive without evidence of disease 24&#xA0;months after the detection of metastatic disease and 90&#xA0;months after the original diagnosis.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The report underscores the current utility of multiple comprehensive approaches for the correct diagnosis and clinical management of patients affected by rare and atypical brain neoplasms. Successful local control of disease and achievement of long-term survival is possible in ATRT patients even in the setting of rhabdoid tumor predisposition syndrome, infant age at diagnosis and metastatic spread of disease, thus justifying the efforts for the management of this severe condition.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Atypical teratoid rhabdoid tumor</kwd>
        <kwd>ATRT</kwd>
        <kwd>SMARCB1/INI1</kwd>
        <kwd>Medulloblastoma</kwd>
        <kwd>MLPA</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p><italic>SMARCB1/INI1</italic> is a highly conserved core subunit of the SWI/SNF family of ATP-dependent chromatin remodeling complexes [<xref ref-type="bibr" rid="B1">1</xref>] and acts as a tumor suppressor gene inactivated in malignant rhabdoid tumors (MRT) of childhood, encompassing renal, soft-tissue and brain cancers [<xref ref-type="bibr" rid="B2">2</xref>] and characterized by <italic>SMARCB1/INI1</italic> genetic inactivation as a primary, recurrent event [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Notably, a consistent fraction of cases carries de-novo <italic>SMARCB1/INI1</italic> constitutional mutations in the setting of the so called &#x201C;rhabdoid tumor predisposition syndrome&#x201D; [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p>
      <p>MRTs of the brain, known as Atypical Teratoid Rhabdoid Tumor (ATRT), were initially considered as a medulloblastoma subgroup with poor prognosis and have been suggested as a separate entity since 1996 [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], but only recently systematic <italic>SMARCB1/INI1</italic> immunohistochemistry and mutational screening in newly diagnosed pediatric brain tumors [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>] has allowed the definition of the incidence, clinical, pathologic and molecular features of ATRT [<xref ref-type="bibr" rid="B11">11</xref>]. ATRT represents an aggressive neoplasm of childhood with a dismal prognosis, presenting a median overall survival of less than 12&#xA0;months and less than 20% progression-free survival at 1&#xA0;year from diagnosis. Particularly, infant age [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>], metastasis at diagnosis [<xref ref-type="bibr" rid="B12">12</xref>] and the status of carrier of rhabdoid tumor predisposition syndrome [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>] invariably lead ATRT patients to rapid lethal outcome, with less than 30% overall survival at 1&#xA0;year. To our knowledge, no long-term survival patient has been reported so far presenting all these three adverse prognosis&#x2019; features.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <sec>
        <title>Patient&#x2019;s history and clinical features</title>
        <p>The patient (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>A), a 24&#xA0;months-old boy affected by mosaic Klinefelter syndrome (47, XXY [14]/46,XY [65]) presented with cerebellar and endocranial hypertension symptoms. Initial MRI examination showed a 3&#xD7;4 cm vermian nodule in the axial plane influencing tri-ventricle hydrocephalon and transependimal liquoral re-absorpion (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>B). He was submitted to surgery with the intent of complete tumor removal but post-operative staging showed multiple hemispherical cerebellar nodules, concurrent spinal metastases at the lumbar and caudal tracts, and cerebrospinal fluid dissemination. Final histological diagnosis, performed at the original neuropathology unit, was medulloblastoma. He was sent to our Unit for adjuvant treatment that, according to the Italian Association of Hematology and Oncology (AIEOP) protocol for high-risk infant medulloblastoma [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>), consisted of sequential high-dose (hd) methotrexate and vincristine, hd-etoposide, hd-cycloposphamide and hd-carboplatin delivered within a 2&#xA0;month time without obtaining a satisfying metastatic tumor response. Craniospinal irradiation according to the hyperfractionated accelerated radiotherapy schedule [<xref ref-type="bibr" rid="B16">16</xref>] was therefore delivered, with a total dose of 31.2&#xA0;Gy to the neuraxis and a boost on posterior fossa up to a total dose of 59.7&#xA0;Gy. Complete response was eventually obtained and two subsequent consolidation courses with high-dose thiotepa were delivered thereafter, followed by rescue autologous hemopoietic stem cells that were harvested after hd-etoposide in the pre-radiant phase.</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold><italic>A</italic></bold><bold>, Schematic representation of the family tree of index case.</bold> Karyotype and <italic>SMARCB1/INI1</italic> molecular evaluation (<bold>E</bold>) is reported (wt= wild type; Arg40X denotes the constitutional mutation found in index case). Present age and age of onset of clinical symptoms is given in years (y). <bold><italic>B</italic></bold>, Brain MRI of primary ATRT lesion. <bold><italic>C</italic></bold>, MRI of metastatic lesion. <bold><italic>D</italic></bold>, Hematoxylin eosin staining and <bold><italic>E</italic></bold>, <italic>SMARCB1/INI1</italic> staining of ATRT tumor from index case, showing absence of <italic>SMARCB1/INI1</italic> protein expression in cancer cells.</p>
          </caption>
          <graphic xlink:href="1471-2407-13-100-1"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Schedules of chemotherapy and radiotherapy.</p>
          </caption>
          <graphic xlink:href="1471-2407-13-100-2"/>
        </fig>
        <p>The child was thereafter asymptomatic until November 2010 when he complained of gait disturbances and lower back pain. The MRI performed showed an intrarachideal spinal lesion extended from L3 to L5 (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>C) that was surgically excised sub-totally. The staging was repeated with whole CNS MRI and cytological cerebrospinal fluid examination and did not show other neoplastic sites. Analysis of this second tumor under central pathology review board concluded for the diagnosis of ATRT, supported by negative <italic>SMARCB1/INI1</italic> staining. Central pathology re-evaluation of primary tumor revealed negative <italic>SMARCB1/INI1</italic> staining, prompting a reassessment of the original diagnosis to ATRT (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>D-E). Parents accepted the new treatment (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>), proposed based on International Society of Pediatric Oncology (SIOP) guidelines for rhabdoid tumors, consisting of chemotherapy alternating adriamycin and vincristine, carboplatin plus etoposide and ifosfamide (ICE regimen) and actinomycin D, cyclophosphamide and vincristine, leading to complete response of spinal residual disease. Due to previous craniospinal irradiation, no intratechal chemotherapy was planned. The systemic treatment finally included one myeloablative course with high-dose carboplatin and thiotepa. Following restoration from aplastic period he was re-irradiated on the spinal tumor bed. Radiation was delivered to the spine and conus medullaris from L3 to S4 and reached a total dose of 39.6 gray (Gy) with a standard fractionation of 1.8&#xA0;Gy/day. The child is now 114&#xA0;months old and is alive without evidence of disease 24&#xA0;months after spinal relapse and 90&#xA0;months after the original diagnosis.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>Microsatellite alleles and sequence polimorphisms of mitochondrial DNA hypervariable regions (HV1 and HV2) detected in constitutional DNA, primary tumor and metastasis of ATRT index case</p>
          </caption>
          <table frame="hsides" rules="groups" border="1">
            <colgroup>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
              <col align="center"/>
            </colgroup>
            <thead valign="top">
              <tr>
                <th align="center">
                  <bold>Marker</bold>
                </th>
                <th align="center">
                  <bold>Costituzional DNA</bold>
                </th>
                <th align="center">
                  <bold>Primary tumor</bold>
                </th>
                <th align="center">
                  <bold>Metastatic tumor</bold>
                </th>
                <th align="center">
                  <bold>Mb position (chr22 start)</bold>
                </th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="center" valign="bottom">
                  <bold>D22S427</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>
                    <italic>(22q11.21)</italic>
                  </bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">97 - 97<hr/></td>
                <td align="center" valign="bottom">97<hr/></td>
                <td align="center" valign="bottom">97<hr/></td>
                <td align="center" valign="bottom">18,591,317<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>D22S257</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>
                    <italic>(22q11.23)</italic>
                  </bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">120 - 128<hr/></td>
                <td align="center" valign="bottom">
                  <italic>128</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">
                  <italic>128</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">23,568,429<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>D22S1174</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>
                    <italic>(22q11.23)</italic>
                  </bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">139 - 141<hr/></td>
                <td align="center" valign="bottom">
                  <italic>139</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">
                  <italic>139</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">24,488,486<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>D22S1154</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>
                    <italic>(22q12.1)</italic>
                  </bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">264 - 266<hr/></td>
                <td align="center" valign="bottom">
                  <italic>264</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">
                  <italic>264</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">26,617,527<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>D22S1163</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>
                    <italic>(22q12.1)</italic>
                  </bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">148 - 162<hr/></td>
                <td align="center" valign="bottom">
                  <italic>162</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">
                  <italic>162</italic>
                  <hr/>
                </td>
                <td align="center" valign="bottom">27,918,651<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>HV1</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">-<hr/></td>
                <td align="center" valign="bottom">16183C<hr/></td>
                <td align="center" valign="bottom">16183C<hr/></td>
                <td align="center" valign="bottom">-<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">16189C<hr/></td>
                <td align="center" valign="bottom">16189C<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">
                  <bold>HV2</bold>
                  <hr/>
                </td>
                <td align="center" valign="bottom">-<hr/></td>
                <td align="center" valign="bottom">263&#xA0;G<hr/></td>
                <td align="center" valign="bottom">263&#xA0;G<hr/></td>
                <td align="center" valign="bottom">-<hr/></td>
              </tr>
              <tr>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
                <td align="center" valign="bottom">309.3C<hr/></td>
                <td align="center" valign="bottom">309.3C<hr/></td>
                <td align="center" valign="bottom">&#xA0;<hr/></td>
              </tr>
              <tr>
                <td align="center">&#xA0;</td>
                <td align="center">&#xA0;</td>
                <td align="center">315.1C</td>
                <td align="center">315.1C</td>
                <td align="center">&#xA0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The patient is at present in the full-course of the primary school and is assisted by a tutor. Indeed, the cognitive and developmental status of the patient was influenced by Klinefelter syndrome, whose symptoms were not properly and early addressed due to cancer occurrence. During the course of the ATRT disease, the patient suffered hydrocephalus at diagnosis and he was affected by posterior fossa syndrome in the post-operative period. He had a direct neuro-cognitive assessment 2&#xA0;years after the end of the first treatment and displayed a full-scale IQ of 68, verbal IQ of 72 and performance IQ of 72, but we lack basal evaluations. For all these reasons, it is not possible to draw any conclusion on the morbidity and cognitive/developmental impact of specific therapies applied.</p>
      </sec>
      <sec>
        <title>Patient&#x2019;s molecular features</title>
        <p>Negative immunostaining for <italic>SMARCB1/INI1</italic> protein prompted us to further investigate <italic>SMARCB1/INI1</italic> gene status in Carnoy&#x2019;s fixed (primary tumor) and formalin-fixed (spinal metastasis), paraffin-embedded biopsies, in order to corroborate the pathological results. <italic>SMARCB1/INI1</italic> exon amplification and sequencing revealed the presence of a homozygous exon 2 c.118C&gt;T (Arg40X) mutation in both the primary and metastatic tumor lesions (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>A).</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p><bold><italic>A-C</italic></bold><bold>, Electropherogram of normal and tumor DNA-derived sequences showing the presence of heterozygous exon 2 c.</bold>118C&gt;T (Arg40X) in (<bold><italic>A</italic></bold>) patient&#x2019;s constitutional DNA and the same homozygous mutation <bold>(</bold><bold><italic>B</italic></bold><bold>)</bold> in tumor samples. <bold><italic>C</italic></bold><bold>,</bold> Parental sample, displaying normal DNA sequence. <bold><italic>D-E</italic></bold>, Fragment analysis (<bold><italic>D</italic></bold>) and histogram (<bold><italic>E</italic></bold>) of MLPA results for <italic>SMARCB1/INI1</italic> gene dosage analysis in primary tumor tissue and in control samples. Red dots indicate peaks corresponding to SMARCB1/INI1 fragments.</p>
          </caption>
          <graphic xlink:href="1471-2407-13-100-3"/>
        </fig>
        <p>Investigation of patient&#x2019;s peripheral blood-derived DNA revealed the presence of the same mutation in heterozygosity (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>B), thus establishing the constitutional origin of the mutation. Both parents and the younger brother carried instead a wild-type sequence (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>C), suggesting the de-novo origin of the mutation in the index case. The c.118C&gt;T (Arg40X) mutation has already been described in malignant rhabdoid tumor [<xref ref-type="bibr" rid="B18">18</xref>] and leads to the creation of a premature stop codon in <italic>SMARCB1/INI1</italic> exon 2.</p>
        <p>Loss of the second allele in tumor tissue as a second hit for <italic>SMARCB1/INI1</italic> inactivation was suggested by sequencing results (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>A) and further supported by multiplex ligation-dependent probe amplification (MLPA) gene dosage analysis that revealed hemizygous deletion of the entire <italic>SMARCB1/INI1</italic> gene and flanking chromosome 22q probes in both tumors (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>D-E). Normal DNAs and samples carrying known <italic>SMARCB1/INI1</italic> imbalances were used as controls. The presence of <italic>SMARCB1/INI1</italic> hemyzigous deletion was confirmed also by Real-time quantitative PCR analysis of <italic>SMARCB1/INI1</italic> copy number by means of relative quantification using standard curve method (not shown).</p>
        <p>In order to study the relationship between the two tumor lesions, they were further investigated by analyzing the status of 22q microsatellite loci and mitochondrial DNA hypervariable regions. The results (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>) indicate a complete identity of the two lesions and therefore support a clonal origin and strongly suggest that the spinal tumor represents a metastatic spread of the primary tumor.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Malignant rhabdoid tumors are lethal neoplasms of infancy, which can affect renal and extrarenal locations, including soft tissues and brain [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Notably, these tumors also represent the sole manifestation of a heritable cancer predisposition syndrome caused by constitutional alterations of <italic>SMARCB1/INI1</italic> tumor suppressor gene [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Overall survival in rhabdoid tumor patients is dismal and survival is worst in the setting of infant patients and patients affected by rhabdoid tumor predisposition syndrome [<xref ref-type="bibr" rid="B5">5</xref>]. In malignant rhabdoid tumors affecting the brain (called Atypical Teratoid Rhabdoid Tumors &#x2013; ATRT), similar results are reported and germline mutations are associated with fatal outcome within two-years from diagnosis [<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p>Outcome improvements in ATRT have been reported with the adoption of high-dose, multimodality chemotherapy regimens [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. Indeed, case reports of long-term survival in ATRT have been described [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>] but, to our knowledge, no case reported so far carried constitutional <italic>SMARCB1/INI1</italic> alterations as our infant index case.</p>
      <p>We here describe a long-term surviving patient affected by syndromic ATRT and who is alive 7.5&#xA0;years after the original diagnosis and 2&#xA0;years after onset of a spinal metastatic lesion. All the analyses performed showed an identical genetic profile between the primary and metastatic ATRT lesions. Although we cannot formally exclude that the two lesions represent the occurrence of two independent primary ATRTs, our genetic analyses as well as the clinical history of the patient, characterized by the presence of metastatic spread since the occurrence of the primary tumor, make this hypothesis very unlikely and support a clonal origin of the two lesions.</p>
      <p>ATRT tumor from proband case displayed a biallelic inactivation of SMARCB1/INI1 gene by heterozygous loss of one allele and Arg40X mutation in the exon 2 of the second allele. This mutation, by causing a premature stop codon, is of obvious pathogenic consequence and has already been reported in the spectrum of mutations occurring in malignant rhabdoid tumors [<xref ref-type="bibr" rid="B18">18</xref>]. Although to our knowledge this is the first report of Arg40X occurrence in a syndromic ATRT patient, such mutation has been already reported in syndromic extracerebral MRT and has functional consequences overlapping those of other exon 2 mutations previously reported in syndromic ATRT patients, such as Arg53X [<xref ref-type="bibr" rid="B5">5</xref>]. These data indicate that Arg40X mutation can occur in both sporadic and syndromic, and in both cerebral and extracerebral MRTs, thus suggesting that no specific genotype-phenotype correlation exists.</p>
      <p>The patient under study was affected by mosaicism for Klinefelter syndrome, the most common human sex chromosome disorder, presenting 18% of peripheral blood lymphocytes with chromosome X aneuploidy and this report represents, to our knowledge, the first association of ATRT with Klinefelter. Despite individual case reports emphasized the association between Klinefelter and specific cancers&#x2019; risk, reviews of epidemiological data do not support a generalized increased risk of cancer in Klinefelter patients [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>], which remains significant only for breast cancer if compared to the general population of males but not of females [<xref ref-type="bibr" rid="B27">27</xref>]. In addition, there is no evidence of recurrent X chromosome abnormalities or X-chromosome gene(s) mutation in ATRT tumor samples analyzed by whole-genome approaches [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B29">29</xref>], so we suggest that the occurrence of ATRT in our patient is unrelated to Klinefelter syndrome. Furthermore, in cancer patients Klinefelter is associated with increased risk of cancer mortality [<xref ref-type="bibr" rid="B27">27</xref>] and, although the risk is variable in different cancer types, Klinefelter did not display a protective effect in any individual tumor type investigated. Therefore, we consider very unlikely the possibility that the constitutional karyotype of the patient may have positively affected the course of ATRT, being responsible for the observed long-term survival.</p>
      <p>The patient presents cognitive and developmental delay, as a consequence of Klinefelter syndrome as well as ATRT treatment complications. In this complex scenario, the lack of multiple neuropsychological assessments during the different disease stages impedes to draw any conclusion on the morbidity and cognitive/developmental impact of specific therapies applied.</p>
      <p>To conclude, the observed successful local control of disease and achievement of long-term survival in our molecularly-proven ATRT patient even in the setting of rhabdoid tumor predisposition syndrome justifies the efforts to advance the management of this severe condition.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec>
        <title>Exon PCR and sequencing</title>
        <p>Mutational analysis was performed by exon amplification and sequencing as previously described [<xref ref-type="bibr" rid="B30">30</xref>]. Primers and PCR conditions are available upon request. PCR products were enzymatically purified with ExoSap (Affymetrix) and sequenced with BigDye Terminator chemistry (Applera). Sequencing products were run on an ABI3130xl genetic analyzer (Applera) and electropherograms were visually inspected. The two strands of mitochondrial DNA hypervariable regions HVS-I and HVSII were amplified and sequenced following standard procedures [<xref ref-type="bibr" rid="B31">31</xref>].</p>
        <sec>
          <title>Multiplex ligation-dependent probe amplification</title>
          <p>For Multiplex ligation-dependent probe amplification (MLPA), tumor DNA (100&#xA0;ng) was subjected to DNA copy number analysis using MLPA kits P258-B1, (MRC-Holland), following manufacturer instructions, together with normal DNA samples and cancer cell line samples with known <italic>SMARCB1/INI1</italic> gene copy number alterations as controls. Fragment separation was performed on an ABI3130xl genetic analyzer (Applera). Raw data peak pattern evaluation was performed using GeneMapper software (Applera) and Coffalyser software was used for data analysis (MRC-Holland). Normal DNAs were used as calibrators and samples with known <italic>SMARCB1/INI1</italic> copy number alterations were used as controls for the sensitivity of the test.</p>
        </sec>
        <sec>
          <title>Real-time quantitative PCR</title>
          <p>Analysis of <italic>SMARCB1/INI1</italic> copy number by real-time quantitative PCR was performed by means of relative quantification using standard curve method [<xref ref-type="bibr" rid="B32">32</xref>], using TaqMan assays 4401631 (Applera) for RPPH1 endogenous control gene and Hs01497967_cn (Applera) for <italic>SMARCB1/INI1</italic>. Standard curve was constructed using normal control DNA and 22q normal copy FFPE controls served as calibrator.</p>
        </sec>
        <sec>
          <title>Microsatellites</title>
          <p>Microsatellite alleles&#x2019; analysis was performed by capillary electrophoresis of fluoresceinated amplification products obtained from peripheral blood- and tumor-derived DNA. PCR products were run on an ABI3130xl genetic analyzer (Applera) and raw data were acquired with GeneMapper software and the peak pattern was visually evaluated.</p>
        </sec>
      </sec>
      <sec>
        <title>Consent</title>
        <p>Parents have given consent for the case report to be published.</p>
      </sec>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>PM, MB, LG, RM carried out the molecular studies. IS, VB, LG, MM carried out the clinical management of the patient. AMB, BP, FG carried out pathologic assessments. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/13/100/prepub">http://www.biomedcentral.com/1471-2407/13/100/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>We gratefully acknowledge patient&#x2019;s family for collaboration. The article is partly supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) and by Fondazione Italiana Neuroblastoma (Progetto Pensiero).</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wilson</surname>
            <given-names>BG</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>CW</given-names>
          </name>
          <article-title>SWI/SNF nucleosome remodellers and cancer</article-title>
          <source>Nat Rev Cancer</source>
          <year>2011</year>
          <volume>11</volume>
          <issue>7</issue>
          <fpage>481</fpage>
          <lpage>492</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc3068</pub-id>
          <pub-id pub-id-type="pmid">21654818</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hollmann</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Hornick</surname>
            <given-names>JL</given-names>
          </name>
          <article-title>INI1-deficient tumors: diagnostic features and molecular genetics</article-title>
          <source>Am J Surg Pathol</source>
          <year>2011</year>
          <volume>35</volume>
          <issue>10</issue>
          <fpage>e47</fpage>
          <lpage>e63</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e31822b325b</pub-id>
          <pub-id pub-id-type="pmid">21934399</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Versteege</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sevenet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rousseau-Merck</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Ambros</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Handgretinger</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Aurias</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer</article-title>
          <source>Nature</source>
          <year>1998</year>
          <volume>394</volume>
          <issue>6689</issue>
          <fpage>203</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1038/28212</pub-id>
          <pub-id pub-id-type="pmid">9671307</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Ambrogio</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sougnez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lawrence</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Auclair</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mora</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Golub</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>CW</given-names>
          </name>
          <article-title>A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers</article-title>
          <source>J Clin Invest</source>
          <year>2012</year>
          <volume>122</volume>
          <issue>8</issue>
          <fpage>2983</fpage>
          <lpage>2988</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI64400</pub-id>
          <pub-id pub-id-type="pmid">22797305</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bourdeaut</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lequin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Brugieres</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Reynaud</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dufour</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Doz</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Andre</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stephan</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Perel</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Oberlin</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Orbach</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bergeron</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rialland</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Freneaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ranchere</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Figarella-Branger</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Audry</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Puget</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Pinas</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Capra</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Mosseri</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Coupier</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Gauthier-Villars</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pierron</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor</article-title>
          <source>Clin Cancer Res</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1795</pub-id>
          <pub-id pub-id-type="pmid">21208904</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sevenet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Sheridan</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Amram</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Schneider</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Handgretinger</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers</article-title>
          <source>Am J Hum Genet</source>
          <year>1999</year>
          <volume>65</volume>
          <issue>5</issue>
          <fpage>1342</fpage>
          <lpage>1348</lpage>
          <pub-id pub-id-type="doi">10.1086/302639</pub-id>
          <pub-id pub-id-type="pmid">10521299</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Fogelgren</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Janss</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Zagzag</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Raffel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rorke</surname>
            <given-names>LB</given-names>
          </name>
          <article-title>Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system</article-title>
          <source>Clin Cancer Res</source>
          <year>2000</year>
          <volume>6</volume>
          <issue>7</issue>
          <fpage>2759</fpage>
          <lpage>2763</lpage>
          <pub-id pub-id-type="pmid">10914721</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rorke</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Packer</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity</article-title>
          <source>J Neurosurg</source>
          <year>1996</year>
          <volume>85</volume>
          <issue>1</issue>
          <fpage>56</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1996.85.1.0056</pub-id>
          <pub-id pub-id-type="pmid">8683283</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Judkins</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Mauger</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ht</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rorke</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms</article-title>
          <source>Am J Surg Pathol</source>
          <year>2004</year>
          <volume>28</volume>
          <issue>5</issue>
          <fpage>644</fpage>
          <lpage>650</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200405000-00013</pub-id>
          <pub-id pub-id-type="pmid">15105654</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Pollack</surname>
            <given-names>IF</given-names>
          </name>
          <article-title>Molecular analysis of pediatric brain tumors</article-title>
          <source>Curr Oncol Rep</source>
          <year>2004</year>
          <volume>6</volume>
          <issue>6</issue>
          <fpage>445</fpage>
          <lpage>452</lpage>
          <pub-id pub-id-type="doi">10.1007/s11912-004-0075-5</pub-id>
          <pub-id pub-id-type="pmid">15485613</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pfister</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Korshunov</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kool</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hasselblatt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Eberhart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>MD</given-names>
          </name>
          <article-title>Molecular diagnostics of CNS embryonal tumors</article-title>
          <source>Acta Neuropathol</source>
          <year>2010</year>
          <volume>120</volume>
          <issue>5</issue>
          <fpage>553</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-010-0751-5</pub-id>
          <pub-id pub-id-type="pmid">20882288</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Dufour</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Beaugrand</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Le Deley</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Bourdeaut</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Andre</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Leblond</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bertozzi</surname>
            <given-names>AI</given-names>
          </name>
          <name>
            <surname>Frappaz</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rialland</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Fouyssac</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Edan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Grill</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Quidot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Varlet</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study</article-title>
          <source>Cancer</source>
          <year>2012</year>
          <volume>118</volume>
          <issue>15</issue>
          <fpage>3812</fpage>
          <lpage>3821</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.26684</pub-id>
          <pub-id pub-id-type="pmid">22180295</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tekautz</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Fuller</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Blaney</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Fouladi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Broniscer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Merchant</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Krasin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dalton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hale</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kun</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Wallace</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gilbertson</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Gajjar</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3&#xA0;years of age and older with radiation therapy and high-dose alkylator-based chemotherapy</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <issue>7</issue>
          <fpage>1491</fpage>
          <lpage>1499</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.05.187</pub-id>
          <pub-id pub-id-type="pmid">15735125</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kordes</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Gesk</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Fruhwald</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Graf</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Leuschner</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Hasselblatt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jeibmann</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Oyen</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Pietsch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Siebert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schneppenheim</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2010</year>
          <volume>49</volume>
          <issue>2</issue>
          <fpage>176</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">19902524</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bruggers</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Bleyl</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Pysher</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Barnette</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Afify</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2011</year>
          <volume>56</volume>
          <issue>7</issue>
          <fpage>1026</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.22757</pub-id>
          <pub-id pub-id-type="pmid">20848638</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gandola</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Massimino</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cefalo</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Solero</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Spreafico</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pecori</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Riva</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Collini</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pignoli</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Giangaspero</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Luksch</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Berretta</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Poggi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Biassoni</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Ferrari</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pollo</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Favre</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sardi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Terenziani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fossati-Bellani</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <issue>4</issue>
          <fpage>566</fpage>
          <lpage>571</lpage>
          <pub-id pub-id-type="pmid">19075266</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Garre'</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Cama</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Milanaccio</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gandola</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Massimino</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dallorso</surname>
            <given-names>S</given-names>
          </name>
          <article-title>New concepts in the treatment of brain tumors in very young children</article-title>
          <source>Expert Rev Neurother</source>
          <year>2006</year>
          <volume>6</volume>
          <issue>4</issue>
          <fpage>489</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.1586/14737175.6.4.489</pub-id>
          <pub-id pub-id-type="pmid">16623648</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sevenet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lellouch-Tubiana</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schofield</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hoang-Xuan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Gessler</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Birnbaum</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Jeanpierre</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Jouvet</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Delattre</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations</article-title>
          <source>Hum Mol Genet</source>
          <year>1999</year>
          <volume>8</volume>
          <issue>13</issue>
          <fpage>2359</fpage>
          <lpage>2368</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/8.13.2359</pub-id>
          <pub-id pub-id-type="pmid">10556283</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="book">
          <person-group person-group-type="editor">Fletcher CCD, Unni KK, Mertens F</person-group>
          <source>Pathology and genetics of tumors of soft tissue and bone, Volume 5</source>
          <year>2002</year>
          <edition>Third</edition>
          <publisher-name>WHO Classification of Tumours</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Louis</surname>
            <given-names>DN</given-names>
          </name>
          <name>
            <surname>Ohgaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wiestler</surname>
            <given-names>OD</given-names>
          </name>
          <name>
            <surname>Cavenee</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Burger</surname>
            <given-names>PC</given-names>
          </name>
          <name>
            <surname>Jouvet</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Scheithauer</surname>
            <given-names>BW</given-names>
          </name>
          <name>
            <surname>Kleihues</surname>
            <given-names>P</given-names>
          </name>
          <article-title>The 2007 WHO classification of tumours of the central nervous system</article-title>
          <source>Acta Neuropathol</source>
          <year>2007</year>
          <volume>114</volume>
          <issue>2</issue>
          <fpage>97</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-007-0243-4</pub-id>
          <pub-id pub-id-type="pmid">17618441</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Finkelstein-Shechter</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Gassas</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mabbott</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bartels</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Tabori</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Janzen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hawkins</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bouffet</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2010</year>
          <volume>32</volume>
          <issue>5</issue>
          <fpage>e182</fpage>
          <lpage>e186</lpage>
          <pub-id pub-id-type="pmid">20495479</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gilman</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bunin</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bendel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Joyce</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rozans</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wall</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Macdonald</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Simon</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kadota</surname>
            <given-names>RP</given-names>
          </name>
          <article-title>Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2011</year>
          <volume>57</volume>
          <issue>3</issue>
          <fpage>506</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.22899</pub-id>
          <pub-id pub-id-type="pmid">21744474</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chi</surname>
            <given-names>SN</given-names>
          </name>
          <name>
            <surname>Zimmerman</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Burger</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Rorke-Adams</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Fisher</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Janss</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mazewski</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Manley</surname>
            <given-names>PE</given-names>
          </name>
          <name>
            <surname>Bowers</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Bendel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rubin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Marcus</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Goumnerova</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ullrich</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Kieran</surname>
            <given-names>MW</given-names>
          </name>
          <article-title>Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <issue>3</issue>
          <fpage>385</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="pmid">19064966</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bouvier</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>De Paula</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Fernandez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Quilichini</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Scavarda</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gentet</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Figarella-Branger</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Atypical teratoid/rhabdoid tumour: 7-year event-free survival with gross total resection and radiotherapy in a 7-year-old boy</article-title>
          <source>Childs Nerv Syst</source>
          <year>2008</year>
          <volume>24</volume>
          <issue>1</issue>
          <fpage>143</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">17968559</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gidwani</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Levy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Goodrich</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weidenheim</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kolb</surname>
            <given-names>EA</given-names>
          </name>
          <article-title>Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system</article-title>
          <source>J Neurooncol</source>
          <year>2008</year>
          <volume>88</volume>
          <issue>2</issue>
          <fpage>211</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="doi">10.1007/s11060-008-9553-1</pub-id>
          <pub-id pub-id-type="pmid">18317689</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zimmerman</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Goumnerova</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Proctor</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Marcus</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Pomeroy</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Chi</surname>
            <given-names>SN</given-names>
          </name>
          <name>
            <surname>Chordas</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kieran</surname>
            <given-names>MW</given-names>
          </name>
          <article-title>Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor</article-title>
          <source>J Neurooncol</source>
          <year>2005</year>
          <volume>72</volume>
          <issue>1</issue>
          <fpage>77</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1007/s11060-004-3115-y</pub-id>
          <pub-id pub-id-type="pmid">15803379</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Swerdlow</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Schoemaker</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Jacobs</surname>
            <given-names>PA</given-names>
          </name>
          <collab>UK Clinical Cytogenetics Group</collab>
          <article-title>Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>97</volume>
          <issue>16</issue>
          <fpage>1204</fpage>
          <lpage>1210</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/dji240</pub-id>
          <pub-id pub-id-type="pmid">16106025</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bojesen</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gravholt</surname>
            <given-names>CH</given-names>
          </name>
          <article-title>Morbidity and mortality in Klinefelter syndrome (47, XXY)</article-title>
          <source>Acta Paediatr</source>
          <year>2011</year>
          <volume>100</volume>
          <issue>6</issue>
          <fpage>807</fpage>
          <lpage>813</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1651-2227.2011.02274.x</pub-id>
          <pub-id pub-id-type="pmid">21414026</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McKenna</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Sansam</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>YJ</given-names>
          </name>
          <name>
            <surname>Greulich</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Thom</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Moreau</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Biegel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Pomeroy</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>CW</given-names>
          </name>
          <article-title>Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability</article-title>
          <source>Mol Cell Biol</source>
          <year>2008</year>
          <volume>28</volume>
          <issue>20</issue>
          <fpage>6223</fpage>
          <lpage>6233</lpage>
          <pub-id pub-id-type="doi">10.1128/MCB.00658-08</pub-id>
          <pub-id pub-id-type="pmid">18710953</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Modena</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lualdi</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Facchinetti</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Galli</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Teixeira</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Pilotti</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sozzi</surname>
            <given-names>G</given-names>
          </name>
          <article-title>SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas</article-title>
          <source>Cancer Res</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>10</issue>
          <fpage>4012</fpage>
          <lpage>4019</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3050</pub-id>
          <pub-id pub-id-type="pmid">15899790</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Giunti</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bernini</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Forni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tucci</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sardi</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Clonality analysis of pediatric multiple tumors: two case reports and laboratory investigation</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2006</year>
          <volume>28</volume>
          <issue>4</issue>
          <fpage>241</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="doi">10.1097/01.mph.0000212909.91770.72</pub-id>
          <pub-id pub-id-type="pmid">16679923</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Schmittgen</surname>
            <given-names>TD</given-names>
          </name>
          <name>
            <surname>Livak</surname>
            <given-names>KJ</given-names>
          </name>
          <article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title>
          <source>Nat Protoc</source>
          <year>2008</year>
          <volume>3</volume>
          <issue>6</issue>
          <fpage>1101</fpage>
          <lpage>1108</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id>
          <pub-id pub-id-type="pmid">18546601</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
